StocksFundsScreenerSectorsWatchlists
ENFN

ENFN - Enfusion, Inc. Stock Price, Fair Value and News

9.55USD-0.11 (-1.14%)Market Closed

Market Summary

ENFN
USD9.55-0.11
Market Closed
-1.14%

ENFN Stock Price

View Fullscreen

ENFN RSI Chart

ENFN Valuation

Market Cap

842.1M

Price/Earnings (Trailing)

139.76

Price/Sales (Trailing)

4.82

EV/EBITDA

37.56

Price/Free Cashflow

39.76

ENFN Price/Sales (Trailing)

ENFN Profitability

Operating Margin

66.97%

EBT Margin

6.58%

Return on Equity

7.78%

Return on Assets

5.53%

Free Cashflow Yield

2.52%

ENFN Fundamentals

ENFN Revenue

Revenue (TTM)

174.5M

Rev. Growth (Yr)

14.73%

Rev. Growth (Qtr)

4.8%

ENFN Earnings

Earnings (TTM)

6.0M

Earnings Growth (Yr)

26.11%

Earnings Growth (Qtr)

-65.92%

Breaking Down ENFN Revenue

Last 7 days

2.5%

Last 30 days

12.1%

Last 90 days

9.6%

Trailing 12 Months

-4.1%

How does ENFN drawdown profile look like?

ENFN Financial Health

Current Ratio

3.44

ENFN Investor Care

Shares Dilution (1Y)

4.34%

Diluted EPS (TTM)

0.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023157.2M163.4M168.6M174.5M
2022121.5M131.6M141.7M150.3M
202187.6M95.6M103.7M111.7M
202000079.6M
201900059.0M

Tracking the Latest Insider Buys and Sells of Enfusion, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 05, 2024
movchan oleg
acquired
-
-
249,701
chief executive officer
Mar 01, 2024
gutowski valeria
sold (taxes)
-9,112
8.67
-1,051
chief accounting officer
Mar 01, 2024
bastone bronwen
acquired
45,162
0.411267
109,812
chief people officer
Mar 01, 2024
herring bradley
acquired
82,763
0.966066
85,671
chief financial officer
Mar 01, 2024
gutowski valeria
acquired
26,322
1.29423
20,338
chief accounting officer
Mar 01, 2024
herring bradley
sold (taxes)
-20,157
8.67
-2,325
chief financial officer
Mar 01, 2024
movchan oleg
sold (taxes)
-35,278
8.67
-4,069
chief executive officer
Mar 01, 2024
movchan oleg
acquired
120,400
8.67
13,887
chief executive officer
Mar 01, 2024
campobasso matthew
acquired
27,085
1.03406
26,193
general counsel
Mar 01, 2024
pawar neal
acquired
-
-
144,176
chief operating officer

1–10 of 50

Which funds bought or sold ENFN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 05, 2024
GAMMA Investing LLC
new
-
611
611
-%
Mar 22, 2024
PNC Financial Services Group, Inc.
sold off
-100
-897
-
-%
Mar 11, 2024
VANGUARD GROUP INC
added
3.26
3,649,030
34,934,700
-%
Mar 01, 2024
READYSTATE ASSET MANAGEMENT LP
unchanged
-
79,433
1,055,490
0.04%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
reduced
-23.71
-223,197
1,051,770
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
13,024
182,001
-%
Feb 15, 2024
Legal & General Group Plc
added
67.49
113,713
253,897
-%
Feb 15, 2024
BARCLAYS PLC
added
493
526,000
622,000
-%
Feb 15, 2024
State of Wyoming
added
75.69
160,712
339,296
0.06%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
171,302
171,302
-%

1–10 of 47

Are Funds Buying or Selling ENFN?

Are funds buying ENFN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ENFN
No. of Funds

Unveiling Enfusion, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
brown capital management llc
14.03%
11,817,661
SC 13G/A
Feb 14, 2024
csl tech holdings llc
13.6%
13,768,183
SC 13G/A
Feb 14, 2024
werner capital llc
5.04%
4,682,016
SC 13G/A
Feb 14, 2024
iconiq strategic partners v, l.p.
8.8%
7,748,000
SC 13G/A
Feb 14, 2024
dragoneer investment group, llc
0%
0
SC 13G/A
Feb 07, 2024
lra ventures, llc
8.46%
7,972,007
SC 13G/A
Jan 19, 2024
malherbe investments llc
10.06%
9,870,386
SC 13G/A
Jun 23, 2023
ftv iv, l.p.
1.48%
31,297,606
SC 13D
Mar 09, 2023
brown capital management llc
10.50%
7,244,171
SC 13G/A
Feb 14, 2023
brown capital management llc
8.70%
6,001,842
SC 13G/A

Recent SEC filings of Enfusion, Inc.

View All Filings
Date Filed Form Type Document
Mar 19, 2024
8-K
Current Report
Mar 12, 2024
10-K
Annual Report
Mar 12, 2024
8-K
Current Report
Mar 12, 2024
S-8
Employee Benefits Plan
Mar 07, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Enfusion, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
290.8B
34.9B
-2.02% 58.72%
70.31
8.34
11.18% 1888.46%
154.4B
37.3B
-4.04% 138.88%
81.81
4.14
16.95% 120.64%
51.1B
5.3B
-7.46% 20.84%
55.75
9.56
9.15% 48.14%
29.5B
2.3B
1.77% 5.63%
59.03
13.01
9.90% -4.45%
18.6B
4.5B
-10.68% -11.09%
29.2
4.11
3.06% 514.65%
MID-CAP
8.0B
620.4M
-0.90% 76.70%
3.0K
12.96
31.48% 103.97%
7.1B
4.4B
3.37% 77.78%
-20.83
1.61
7.53% 78.52%
3.4B
881.7M
-7.47% 39.67%
42.72
3.89
4.64% 44.42%
3.4B
970.0M
0.90% -15.87%
-19.13
3.53
13.46% 43.89%
2.8B
296.4M
-23.52% 3.78%
-10.47
9.6
11.14% -3.59%
2.3B
228.1M
11.21% 0.23%
26.04
9.97
18.99% 599.09%
SMALL-CAP
1.2B
413.5M
0.63% -1.64%
92.02
2.88
-1.65% -71.35%
209.1M
572.4M
-34.08% -83.55%
-1.06
0.37
-19.38% -489.49%
193.8M
119.1M
-15.38% -50.03%
-21.03
1.63
24.27% 36.31%
153.0M
31.3M
50.34% 89.84%
-26.05
4.88
4.69% 43.72%

Enfusion, Inc. News

Latest updates
Defense World03 Apr 202408:24 am

Enfusion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Revenue4.8%46,48644,35742,72140,97140,51739,15136,54034,14131,85329,04526,44924,353--
Cost Of Revenue7.7%15,62414,50714,20813,30213,29611,97410,84710,98310,1648,0956,7776,809--
Gross Profit3.4%30,86229,85028,51327,66927,22127,17725,69323,15821,68920,95019,67217,544--
Operating Expenses5.8%28,72827,16126,06722,99025,84924,23629,59935,529314,18816,04713,76211,741--
  S&GA Expenses0.9%5,5525,5035,2774,0866,0017,2787,5758,43239,4024,9014,2643,158--
EBITDA Margin11.1%0.12*0.11*0.11*0.08*-0.04*-2.12*-2.28*-2.39*-2.44*0.08*0.09*0.09*0.10*0.25*
Interest Expenses------4.001.006.005261,4851,4101,392--
Income Taxes248.8%1,280367188396418287219150-125154249302--
Earnings Before Taxes-28.0%2,1803,0281,1865,0901,2062,885-3,906-12,374-294,0203,4474,5004,411--
EBT Margin5.5%0.07*0.06*0.06*0.03*-0.08*-2.17*-2.33*-2.46*-2.52*0.04*0.05*0.05*0.06*0.22*
Net Income-65.9%6231,8286292,9454941,539-2,422-7,265-169,9693,2934,2514,109--
Net Income Margin-1.3%0.03*0.03*0.03*0.02*-0.05*-1.26*-1.34*-1.40*-1.42*0.04*0.04*0.05*0.05*0.21*
Free Cashflow0.1%9,5099,4993,799-1,6265,7756,920798-7,268-7,453-4,2814,987-1,585--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q32021Q22020Q4
Assets7.1%10910294.0012112411611010510689.0073.0056.0039.00
  Current Assets12.6%70.0062.0060.0087.0097.0096.0090.0086.0090.0036.00--29.00
    Cash Equivalents12.5%36.0032.0028.0055.0063.0064.0057.0056.0064.008.00-0.0014.00
  Net PPE1.0%18.0018.0018.0017.0016.0015.0016.0015.0013.0012.00--9.00
Liabilities10.6%31.0028.0022.0022.0020.0012.0010.008.009.00109--107
  Current Liabilities24.0%20.0016.0014.0014.0017.0012.0010.008.008.0016.00--11.00
Shareholder's Equity52.7%77.0051.0072.0099.0065.0010310097.0097.000.00-0.00-233
  Retained Earnings0.4%-172-173-175-176-178-179-180-178-171----
  Additional Paid-In Capital1.0%227225224240244241241234227----
Shares Outstanding-100.0%-88.0088.0089.0085.0085.0084.0083.0083.00----
Minority Interest5.6%24.0023.0024.0035.0038.0042.0041.0042.0042.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Cashflow From Operations-45.6%6,58612,1066,0189247,5217,8422,890-4,097-5,812-2,3097,036767---
  Share Based Compensation29.8%3,4042,6232,578-1,1474,2054387,66812,682-------
Cashflow From Investing12.0%-2,295-2,607-2,219-2,550-1,746-922-2,092-3,171-1,641-1,972-2,049-2,352---
Cashflow From Financing89.1%-579-5,309-30,842-6,353-7,042-20.00-92.00-80563,382-1,788-2,581-164---

ENFN Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
REVENUES:   
Total revenues$ 174,535$ 150,349$ 111,700
COST OF REVENUES:   
Total cost of revenues57,64147,10031,845
Gross profit116,894103,24979,855
OPERATING EXPENSES:   
General and administrative64,63568,764150,614
Sales and marketing20,41829,28651,725
Technology and development19,89317,163153,400
Total operating expenses104,946115,213355,739
Income (loss) from operations11,948(11,964)(275,884)
NON-OPERATING INCOME (EXPENSE):   
Payment to related party(1,501)  
Interest income (expense), net1,641413(4,594)
Other expense, net(604)(638)(1,185)
Total non-operating income (expense)(464)(225)(5,779)
Income (loss) before income taxes11,484(12,189)(281,663)
Income taxes2,2311,074579
Net income (loss)9,253(13,263)(282,242)
Net income (loss) attributable to non-controlling interests3,228(5,609)(123,925)
Net income (loss) attributable to Enfusion, Inc.$ 6,025$ (7,654)$ (158,317)
Net income (loss) per Class A common shares attributable to Enfusion, Inc.:   
Net income (loss) per share of Class A common stock--Basic$ 0.07$ (0.10)$ (2.26)
Net income (loss) per share of Class A common stock--Diluted$ 0.07$ (0.10)$ (2.26)
Weighted Average number of Class A common shares outstanding:   
Weighted Average number of Class A common shares outstanding, Basic88,20285,39383,045
Weighted Average number of Class A common shares outstanding, Diluted129,42985,39383,045
Platform subscriptions   
REVENUES:   
Total revenues$ 161,519$ 138,868$ 103,259
COST OF REVENUES:   
Total cost of revenues50,70240,01727,195
Managed services   
REVENUES:   
Total revenues11,7739,8217,119
COST OF REVENUES:   
Total cost of revenues6,5146,6924,425
Other   
REVENUES:   
Total revenues1,2431,6601,322
COST OF REVENUES:   
Total cost of revenues$ 425$ 391$ 225

ENFN Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 35,604$ 62,545
Accounts receivable, net28,06925,855
Prepaid expenses5,0096,105
Other current assets1,1702,303
Total current assets69,85296,808
Property, equipment, and software, net18,31415,759
Right-of-use-assets, net14,3046,732
Other assets6,5024,484
Total assets108,972123,783
Current liabilities:  
Accounts payable2,2121,685
Accrued expenses and other current liabilities13,84111,665
Current portion of lease liabilities4,2564,030
Total current liabilities20,30917,380
Lease liabilities, net of current portion11,1812,959
Total liabilities31,49020,339
Commitment and contingencies (Note 8)
Stockholders' Equity:  
Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Additional paid-in capital226,877244,260
Accumulated deficit(172,932)(178,863)
Accumulated other comprehensive loss(406)(504)
Total stockholders' equity attributable to Enfusion, Inc.53,66665,007
Non-controlling interests23,81638,437
Total stockholders' equity77,482103,444
Total liabilities and stockholders' equity108,972123,783
Common Class A  
Stockholders' Equity:  
Common stock8871
Common Class B  
Stockholders' Equity:  
Common stock$ 39$ 43
ENFN
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.
 CEO
 WEBSITEenfusion.com
 INDUSTRYSoftware - Apps
 EMPLOYEES1006

Enfusion, Inc. Frequently Asked Questions


What is the ticker symbol for Enfusion, Inc.? What does ENFN stand for in stocks?

ENFN is the stock ticker symbol of Enfusion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enfusion, Inc. (ENFN)?

As of Wed Apr 10 2024, market cap of Enfusion, Inc. is 842.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENFN stock?

You can check ENFN's fair value in chart for subscribers.

What is the fair value of ENFN stock?

You can check ENFN's fair value in chart for subscribers. The fair value of Enfusion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enfusion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENFN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enfusion, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENFN is over valued or under valued. Whether Enfusion, Inc. is cheap or expensive depends on the assumptions which impact Enfusion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENFN.

What is Enfusion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 10 2024, ENFN's PE ratio (Price to Earnings) is 139.76 and Price to Sales (PS) ratio is 4.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENFN PE ratio will change depending on the future growth rate expectations of investors.